BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 31395084)

  • 1. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
    Edris A; De Feyter S; Maes T; Joos G; Lahousse L
    Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis.
    Edris A; Lahousse L
    Minerva Med; 2021 Oct; 112(5):573-581. PubMed ID: 33988014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
    Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
    J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
    Ramonell RP; Iftikhar IH
    Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies in severe asthma: is it worth it?
    Calzetta L; Matera MG; Rogliani P
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):517-520. PubMed ID: 31104515
    [No Abstract]   [Full Text] [Related]  

  • 8. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the risk of infection events in patients with asthma receiving
    Giossi R; Pani A; Schroeder J; Scaglione F
    Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials.
    Cabon Y; Molinari N; Marin G; Vachier I; Gamez AS; Chanez P; Bourdin A
    Clin Exp Allergy; 2017 Jan; 47(1):129-138. PubMed ID: 27859832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
    Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
    J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
    Liu T; Wang F; Wang G; Mao H
    Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis.
    He LL; Zhang L; Jiang L; Xu F; Fei DS
    Int Immunopharmacol; 2018 Nov; 64():223-231. PubMed ID: 30199847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
    Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
    J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
    Akenroye A; Lassiter G; Jackson JW; Keet C; Segal J; Alexander GC; Hong H
    J Allergy Clin Immunol; 2022 Nov; 150(5):1097-1105.e12. PubMed ID: 35772597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
    Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
    Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.